Advertising
Showing 1 to 12 of 12 entries
  • «
  • 1
  • »
PAST TOP PICK
(A Top Pick Sep 20/21, Down 28%) Canada's largest pharmacy to LTC facilities. Two transformative acquisitions. Over 20% market share. Expects organic and acquisition sales growth and margin improvement. Telehealth. Distributing supplies. Stable, recession-proof, demographic tailwinds, easy valuation.
Healthcare
STRONG BUY
It was formerly Centric Health which had many businesses and a lot of debt. They paid the debt and sold businesses. Now, they're 100% focussed on Canada's #1 institutional pharmacy which distributes to seniors' homes. They're automating fulfillment centres to expand margins. Again demographics are a tailwind. Tuck-in acquisitions are coming and are integrating some now, so there are expected costs. He holds a large position. Trades at a reasonable valuation. A safe growing stock.
Healthcare
WATCH
Interesting business model. Pharmacy services to LTC. Technology automates everything. Continues to add facilities, so revenue and cashflow increasing. Reasonable multiple. Trades thinly, not a lot of institutional volume. Small cap selloff. On his radar.
Healthcare
STRONG BUY
The #1 institutional pharmacy player with 23% market share. Stock did well last year, cheap now. Organic and acquisition growth. Becoming really well managed. Automating fulfillment centres to improve margins. Equity raises caused it to tread water. Solid baseline, should trend up nicely. Demographic tailwind. Getting into medical supply distribution.
Healthcare
TOP PICK
Canada's largest pharmacy provider to LTC homes. Winning new business from competitors. Getting into telehealth. Launching pharmacy at your door, for seniors living at home. Demographics behind it. Super well managed. Bargain basement price. Organic and acquisition growth. No dividend. (Analysts’ price target is $8.69)
Healthcare
TOP PICK
Canada's number one provider of pharmacy services to long term care facilities. They have over 20% market share. They are also into tele-health services. The consolidation play is still in the early stages. (Analysts’ price target is $8.81)
Healthcare
PAST TOP PICK
(A Top Pick Jun 16/20, Up 37%) One of his biggest positions. Still buying at these levels. Safe way to play healthcare with aging demographics and industry consolidation. Unaffected by the lockdown. Several large, transformative acquisitions. #1 institutional pharmacy player in Canada, with 20% of the market. Launching telemedicine services. Great growth for many years to come.
Healthcare
PAST TOP PICK
(A Top Pick Jun 16/20, Up 34%) One of his biggest positions. Rose during pandemic. Unaffected by lockdowns. Several large, accretive acquisitions, making them the largest player in Canada at 20% of the institutional pharmacy market. Huge tailwinds with the seniors demographic. Focused strategy, well managed, more consolidation to come, plus organic growth.
Healthcare
BUY

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. Trades at under 2x sales and growth is positive. The stock is doing well. Debt remains high and they are losing money. Insiders are committed, owning 21% and continue to buy. The acquisition adds $170M to sales. Has held gains this year and is a better mid-cap name in the space. Unlock Premium - Try 5i Free

Healthcare
PAST TOP PICK
(A Top Pick Apr 28/20, Up 12%) They did a 20-1 share consolidation, so the stock is up a lot, and changed their name. It's Canada biggest institutional pharmacy serving senior care. The stock was untouched by Covid, because seniors still needed their meds. Also, they made several big acquisitions, and they winning business from peers. They're launching telemedicine services and, with Think Research, will supply virtual care to seniors facilities they already serve. In the next 15 years, the number of seniors will double in Canada. This is a safe way to play Canada's demographics. CRRX fixed their balance sheet, too. It trades a reasonable PE. He owns 3% of this company.
Healthcare
PAST TOP PICK

(A Top Pick Feb 24/20, Up 26%) It was Centric Health. It is a large position for him and a core holding. He would buy it again. There is powerful demographic tailwinds for them. They are consolidating a very fragmented industry in Canada. There are huge cost synergies.

Healthcare
HOLD

Billy Kawasaki’s Insights - Picks from 5i Research. The company continues to transform and has done well. The market cap has grown and revenues should be over $200M next year. Debt remains high however, and it has negative cash flow. Top line growth over the next two years is expected to be in the range of 20%-30%. Unlock Premium - Try 5i Free

Healthcare
Showing 1 to 12 of 12 entries
  • «
  • 1
  • »

CareRx(CRRX-T) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 3

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 3

Stockchase rating for CareRx is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

CareRx(CRRX-T) Frequently Asked Questions

What is CareRx stock symbol?

CareRx is a Canadian stock, trading under the symbol CRRX-T on the Toronto Stock Exchange (CRRX-CT). It is usually referred to as TSX:CRRX or CRRX-T

Is CareRx a buy or a sell?

In the last year, 3 stock analysts published opinions about CRRX-T. 3 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for CareRx.

Is CareRx a good investment or a top pick?

CareRx was recommended as a Top Pick by on . Read the latest stock experts ratings for CareRx.

Why is CareRx stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is CareRx worth watching?

3 stock analysts on Stockchase covered CareRx In the last year. It is a trending stock that is worth watching.

What is CareRx stock price?

On 2022-08-16, CareRx (CRRX-T) stock closed at a price of $3.77.